Dario Health Corp. DRIO
We take great care to ensure that the data presented and summarized in this overview for DarioHealth Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DRIO
View all-
Nantahala Capital Management, LLC New Canaan, CT1.69MShares$1.18 Million0.05% of portfolio
-
Appian Way Asset Management LP New York, NY1.28MShares$896,6160.2% of portfolio
-
Phoenix Holdings Ltd. Givatayim, L31.13MShares$788,7150.01% of portfolio
-
Y.D. More Investments LTD Ramat Gan, L3654KShares$457,6470.03% of portfolio
-
Lasry Marc New York, NY465KShares$325,4353.53% of portfolio
-
Geode Capital Management, LLC Boston, MA364KShares$254,7810.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA364KShares$254,5720.0% of portfolio
-
Amh Equity LTD250KShares$175,0000.25% of portfolio
-
Royal Bank Of Canada Toronto, A6184KShares$129,0630.0% of portfolio
-
Dlk Investment Management, LLC Solana Beach, CA152KShares$106,1610.04% of portfolio
Latest Institutional Activity in DRIO
Top Purchases
Top Sells
About DRIO
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Insider Transactions at DRIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2025
|
Chen Franco Yehuda Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+50.0%
|
-
|
|
Feb 24
2025
|
Jon H. Kaplan Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+21.19%
|
-
|
|
Nov 12
2024
|
Steven Charles Nelson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+8.33%
|
$0
$0.91 P/Share
|
|
Sep 11
2024
|
Steven Charles Nelson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+9.09%
|
$0
$0.8 P/Share
|
|
Sep 10
2024
|
Steven Charles Nelson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+10.0%
|
$0
$0.84 P/Share
|
|
Sep 09
2024
|
Steven Charles Nelson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+11.11%
|
$0
$0.8 P/Share
|
|
Sep 06
2024
|
Steven Charles Nelson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+12.5%
|
$0
$0.84 P/Share
|
|
Sep 05
2024
|
Steven Charles Nelson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+14.29%
|
$0
$0.82 P/Share
|
|
Aug 27
2024
|
Erez Raphael Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.26%
|
$0
$0.88 P/Share
|
|
Aug 23
2024
|
Steven Charles Nelson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+16.67%
|
$0
$0.95 P/Share
|
|
Aug 22
2024
|
Steven Charles Nelson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+20.0%
|
$0
$0.94 P/Share
|
|
Aug 21
2024
|
Erez Raphael Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.26%
|
$0
$0.95 P/Share
|
|
Aug 21
2024
|
Steven Charles Nelson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+25.0%
|
$0
$0.93 P/Share
|
|
Aug 20
2024
|
Erez Raphael Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.26%
|
$0
$0.93 P/Share
|
|
Aug 20
2024
|
Steven Charles Nelson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+33.33%
|
$0
$0.94 P/Share
|
|
Aug 19
2024
|
Erez Raphael Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.26%
|
$0
$0.9 P/Share
|
|
Aug 19
2024
|
Steven Charles Nelson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$0
$0.92 P/Share
|
|
Aug 16
2024
|
Erez Raphael Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.13%
|
$0
$0.9 P/Share
|
|
Mar 06
2024
|
Hila Karah Director |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+24.2%
|
-
|
|
Mar 06
2024
|
Jon H. Kaplan Director |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+50.0%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 80K shares |
|---|---|
| Grant, award, or other acquisition | 530K shares |